(UroToday.com) The ANZUP annual scientific meeting’s clinical trials session included an update in renal cell carcinoma (RCC) provided by Dr. David Pook and Dr. Craig Gedye. Dr. Pook started by highlighting that non-clear cell RCC account for ~25% of RCC cases with less clear treatment guidelines compared to clear cell RCC. The UNISON trial is evaluating nivolumab followed by ipilimumab + nivolumab in advanced non-clear cell RCC (ANZUP 1602). The hypothesis of this trial is that patients are treated with nivolumab monotherapy upfront and that those who are nivolumab refractory may benefit from nivolumab + ipilimumab combination therapy.